Founded by leading cancer genomics researchers and clinicians, Predicta is a precision oncology company developing novel diagnostic and therapeutic products. The company's non-invasive diagnostics initially focus on multiple myeloma and evaluate patients' immune system cells, equipping physicians with the unique ability to determine the likelihood of a patient responding to immunotherapies. Leveraging extensive genomic and transcriptomic patient data, Predicta is also building a one-of-a-kind clinical database for identifying new therapeutic targets.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/16/24 | $5,200,000 | Seed |
Illumina Ventures Oetgen Family The American Cancer Society Bright Edge The Engine  Time Boost Capital | undisclosed |
